Physician profile
David Markham
NPI 1871608489
$5,569.01
in general payments reported to CMS, 2019-2025
32 companies · $1,691 in 2025
The $1,691 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,048 · 2024: $1,830 · 2025: $1,691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,287 · Travel and Lodging: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,287.10 |
| Travel and Lodging | $281.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,005.43 | 2023-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Cvrx, INC. | $1,208.29 | 2023-2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $258.36 | 2023-2025 | Verquvo, Winrevair, Capvaxive |
| Alnylam Pharmaceuticals INC. | $257.77 | 2023-2025 | Amvuttra, Onpattro |
| E.R. Squibb & Sons, L.L.C. | $210.00 | 2023-2025 | Camzyos, Eliquis |
| Pfizer INC. | $191.10 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.94 | 2023-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $180.05 | 2023-2025 | Farxiga, Wainua, Brilinta |
| Novartis Pharmaceuticals Corporation | $124.01 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $98.49 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $90.91 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $82.30 | 2025 | Lifevest |
| Takeda Pharmaceuticals U.S.A., INC. | $67.54 | 2025 | Livtencity |
| Bayer Healthcare Pharmaceuticals INC. | $61.74 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $59.15 | 2023 | Inpefa |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $52.76 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Actelion Pharmaceuticals US, INC. | $45.19 | 2023-2025 | Opsumit, Uptravi |
| Boston Scientific Corporation | $44.76 | 2023-2024 | Watchman Flx |
| Depuy Synthes Sales INC. | $42.95 | 2024 | Zipfix |
| Bridgebio Pharma, INC. | $40.74 | 2025 | Attruby |
| Astellas Pharma US INC | $34.98 | 2025 | Cresemba |
| Heartflow, INC. | $31.36 | 2024-2025 | |
| Esperion Therapeutics, INC. | $25.11 | 2024 | Nexletol |
| Invivyd INC | $24.35 | 2025 | Pemgarda |
| Inspire Medical Systems, INC. | $22.54 | 2024 | Inspire |
| Kiniksa Pharmaceuticals International, Plc | $19.61 | 2024 | Arcalyst |
| Chiesi USA, INC. | $18.17 | 2024 | Kengreal |
| Amgen INC. | $17.74 | 2023 | Repatha |
| Argon Medical Devices, INC. | $16.36 | 2025 | Clot Management |
| Scpharmaceuticals INC. | $15.85 | 2025 | |
| Janssen Pharmaceuticals, INC | $15.29 | 2024 | Xarelto |
| Nuwellis, INC. | $15.17 | 2025 | Aquadex Smartflow Console |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Markham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.